Erratum: Proceedings from the 2nd European Clinical Consensus Conference for device-based therapies for hypertension: state of the art and considerations for the future (European Heart Journal (2017) DOI: 10.1093/eurheartj/ehx215);Proceedings from the 2nd European clinical consensus conference for device-based therapies for hypertension: State of the art and considerations for the future

European Heart Journal

Volumn 38, Issue 44, 2017, Pages 3272-3281a

  Mahfoud, Felix ^a,b   Schmieder, Roland E ^c   Azizi, Michel ^d,e,f   Pathak, Atul ^g,h   Sievert, Horst ^i,j   Tsioufis, Costas ^k   Zeller, Thomas ^l   Bertog, Stefan ⁱ   Blankestijn, Peter J ^m   Böhm, Michael ^a   Burnier, Michel ⁿ   Chatellier, Gilles ^d,e   Zaleski, Isabelle Durand ^o,p   Ewen, Sebastian ^a   Grassi, Guido ^q,r   Joner, Michael ^s,t   Kjeldsen, Sverre E ^u,v   Lobo, Melvin D ^w   Lotan, Chaim ^x   Lüscher, Thomas Felix ^y   Parati, Gianfranco ^q   Rossignol, Patrick ^z   Ruilope, Luis ^aa,ab   Sharif, Faisal ^ac   Van Leeuwen, Evert ^ad   Volpe, Massimo ^ae   Windecker, Stephan ^af   Witkowski, Adam ^ag   Wijns, William ^ac,ah   more..

^a SAARLAND UNIVERSITY   (Germany)

^b Massachusetts Institute of Technology   (United States)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^f INSERM   (France)

^g CLINIQUE PASTEUR   (France)

^h CANCER RESEARCH CENTER OF TOULOUSE   (France)

ⁱ Cardiovascular Center Frankfurt CVC   (Germany)

^j ANGLIA RUSKIN UNIVERSITY   (United Kingdom)

^k UNIVERSITY OF ATHENS   (Greece)

^l UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

^m UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

ⁿ LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^o HÔTEL DIEU   (France)

^p HENRI MONDOR HOSPITAL   (France)

^q UNIVERSITY OF MILANO BICOCCA   (Italy)

^r IRCCS MULTIMEDICA   (Italy)

^s TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^t Deutsches Zentrum Für Herz Kreislaufforschung EV   (Germany)

^u OSLO UNIVERSITY HOSPITAL   (Norway)

^v UNIVERSITY OF OSLO   (Norway)

^w QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^x HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^y UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^z UNIVERSITY HOSPITAL OF NANCY   (France)

^aa HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^ab UNIVERSIDAD EUROPEA DE MADRID   (Spain)

^ac NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^ad RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^ae SAPIENZA UNIVERSITY OF ROME   (Italy)

^af UNIVERSITY OF BERN   (Switzerland)

^ag INSTITUTE OF CARDIOLOGY   (Poland)

^ah Saolta University Health Care Group   (Ireland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

SPIRONOLACTONE;

ARTERIOVENOUS FISTULA; BLOOD PRESSURE REGULATION; CAROTID SINUS PRESSORECEPTOR REFLEX; CONSENSUS; DEVICE THERAPY; FUTUROLOGY; HYPERTENSION; KIDNEY DENERVATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESISTANT HYPERTENSION; REVIEW; BLOOD PRESSURE; CATHETER ABLATION; DEVICES; EQUIPMENT DESIGN; EUROPE; HUMAN; INNERVATION; KIDNEY; MEDICAL SOCIETY; ORGANIZATION; PATHOPHYSIOLOGY; PHYSIOLOGY; PRACTICE GUIDELINE; SYMPATHECTOMY;

BLOOD PRESSURE; CATHETER ABLATION; CONGRESSES AS TOPIC; CONSENSUS; EQUIPMENT DESIGN; EUROPE; HUMANS; HYPERTENSION; KIDNEY; PRACTICE GUIDELINES AS TOPIC; SOCIETIES, MEDICAL; SYMPATHECTOMY;

EID: 85021253377     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/EURHEARTJ/EHX290     Document Type: Erratum

References (52)

1. Freis ED. Effects of treatment on morbidity in hypertension: Results in patients with diastolic blood pressures averaging 115 through 129 mmHg. JAMA 1967;202:1028-1034.
2. Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, Chen J, He J. Global disparities of hypertension prevalence and control. Circulation 2016;134:441-450.
3. Marshall IJ, Wolfe CDA, McKevitt C. Lay perspectives on hypertension and drug adherence: Systematic review of qualitative research. BMJ 2012;345:e3953.
4. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, Christiaens T, Cifkova R, Backer GD, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F, Burnier M, Ambrosioni E, Caufield M, Coca A, Olsen MH et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Hear J 2013;34:2159-2219.
5. Mahfoud F, Luscher TF, Andersson B, Baumgartner I, Cifkova R, DiMario C, Doevendans P, Fagard R, Fajadet J, Komajda M, LeFevre T, Lotan C, Sievert H, Volpe M, Widimsky P, Wijns W, Williams B, Windecker S, Witkowski A, Zeller T, Bohm M. Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. Eur Heart J 2013;34:2149-2157.
6. Mahfoud F, Bohm M, Azizi M, Pathak A, Durand Zaleski I, Ewen S, Tsioufis K, Andersson B, Blankestijn PJ, Burnier M, Chatellier G, Gafoor S, Grassi G, Joner M, Kjeldsen SE, Luscher TF, Lobo MD, Lotan C, Parati G, Redon J, Ruilope L, Sudano I, Ukena C, Leeuwen EV, Volpe M, Windecker S, Witkowski A, Wijns W, Zeller T, Schmieder RE. Proceedings from the European clinical consensus conference for renal denervation: Considerations on future clinical trial design. Eur Heart J 2015;36:2219-2227.
7. Bohm M, Linz D, Ukena C, Esler M, Mahfoud F. Renal denervation for the treatment of cardiovascular high risk-hypertension or beyond? Circ Res 2014;115:400-409.
8. Smithwick RH. Surgical treatment of hypertension. Am J Med 1948;4:744-759.
9. Bhatt DL, Kandzari DE, O'neill WW, D'agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen S. A, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL. A controlled trial of renal denervation for resistant hypertension. N Eng J Med 2014;370:1393-1401.
10. Azizi M, Sapoval M, Gosse P, Monge M, Bobrie G, Delsart P, Midulla M, Mounier-Vehier C, Courand PY, Lantelme P, Denolle T, Dourmap-Collas C, Trillaud H, Pereira H, Plouin PF, Chatellier G. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): A multicentre, open-label, randomised controlled trial. Lancet 2015;385:1957-1965.
11. Krum H, Schlaich MP, Sobotka PA, Bohm M, Mahfoud F, Rocha-Singh K, Katholi R, Esler MD. Percutaneous renal denervation in patients with treatment-resistant hypertension: Final 3-year report of the Symplicity HTN-1 study. Lancet 2014;383:622-629.
12. Persu A, Jin Y, Azizi M, Baelen M, Volz S, Elvan A, Severino F, Rosa J, Adiyaman A, Fadl Elmula FE, Taylor A, Pechere-Bertschi A, Wuerzner G, Jokhaji F, Kahan T, Renkin J, Monge M, Widimsky P, Jacobs L, Burnier M, Mark PB, Kjeldsen SE, Andersson B, Sapoval M, Staessen JA. Blood pressure changes after renal denervation at 10 European expert centers. J Hum Hypertens 2014;28:150-156.
13. Ng FL, Saxena M, Mahfoud F, Pathak A, Lobo MD. Device-based therapy for hypertension. Curr Hypertens Rep 2016;18:61.
14. Lobo MD, Sobotka PA, Pathak A. Interventional procedures and future drug therapy for hypertension. Eur Heart J 2016; doi: 10.1093/eurheartj/ehw303.
15. Williams B, Macdonald TM, Morant S, Webb DJ, Sever P, McInnes G, Ford I, Cruickshank JK, Caulfield MJ, Salsbury J, Mackenzie I, Padmanabhan S, Brown MJ. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): A randomised, double-blind, crossover trial. Lancet 2015;386:2059-2068.
16. Rosa J, Widimsky P, Waldauf P, Lambert L, Zelinka T, Taborsky M, Branny M, Tousek P, Petrak O,Curila K, Bednar F, Holaj R,Strauch B, Vaclavik J, Nykl I, Kratka Z, Kocianova E, Jiravsky O, Rappova G, Indra T, Widimsky J. Role of adding spironolactone and renal denervation in true resistant hypertension: Oneyear outcomes of randomized PRAGUE-15 study. Hypertension 2016;67:397-403.
17. Sprint Research Group Wright JT, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015;373:2103-2116.
18. Leung AA, Nerenberg K, Daskalopoulou SS, McBrien K, Zarnke KB, Dasgupta K, Cloutier L, Gelfer M, Lamarre-Cliche M, Milot A, Bolli P, Tremblay G, McLean D, Tobe SW, Ruzicka M, Burns KD, Vallee M, Prasad GVR, Lebel M, Feldman RD, Selby P, Pipe A, Schiffrin EL, McFarlane PA, Oh P, Hegele RA, Khara M, Wilson TW, Penner SB, Burgess E et al. Hypertension Canada's 2016 Canadian hypertension education program guidelines for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol 2016;32:569-588.
19. Kjeldsen SE, Berge E, Bangalore S, Messerli FH, Mancia G, Holzhauer B, Hua TA, Zappe D, Zanchetti A, Weber MA, Julius S. No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial. Blood Press 2016;25:83-92.
20. Verdecchia P, Reboldi G, Angeli F, Trimarco B, Mancia G, Pogue J, Gao P, Sleight P, Teo K, Yusuf S. Systolic diastolic blood pressure changes in relation with myocardial infarction and stroke in patients with coronary artery disease. Hypertension 2015;65:108-114.
21. SPS-3 Study Group. Blood-pressure targets in patients with recent lacunar stroke: The SPS3 randomised trial. Lancet 2013;382:507-515.
22. ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff DC, Grimm RH, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT, Gerstein HC, Ismail-Beigi F. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575-1585.
23. Kjeldsen SE, Lund-Johansen P, Nilsson PM, Mancia G. Unattended blood pressure measurements in the systolic blood pressure intervention trial: Implications for entry and achieved blood pressure values compared with other trials. Hypertension 2016;67:808-812.
24. Filipovsky J, Seidlerova J, Kratochvil Z, Karnosova P, Hronova M, Mayer O. Automated compared to manual office blood pressure and to home blood pressure in hypertensive patients. Blood Press 2016;25:228-234.
25. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels-updated overview and meta-analyses of randomized trials. J Hypertens 2016;34:613-622.
26. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering treatment in hypertension: 8. Outcome reductions vs. discontinuations because of adverse drug events-meta-analyses of randomized trials. J Hypertens 2016;34:1451-1463.
27. Parati G, Stergiou G, O'brien E, Asmar R, Beilin L, Bilo G, Clement D, la Sierra A, de Leeuw P, de Dolan E, Fagard R, Graves J, Head GA, Imai Y, Kario K, Lurbe E, Mallion JM, Mancia G, Mengden T, Myers M, Ogedegbe G, Ohkubo T, Omboni S, Palatini P, Redon J, Ruilope LM, Shennan A, Staessen JA, vanMontfrans G, Verdecchia P et al. European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens 2014;32:1359-1366.
28. Goldberg EM, Levy PD. New approaches to evaluating and monitoring blood pressure. Curr Hypertens Rep 2016;18:49.
29. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, Chalmers J, Rodgers A, Rahimi K. Blood pressure lowering for prevention of cardiovascular disease and death: A systematic review and meta-analysis. Lancet 2016;387:957-967.
30. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and metaregression analyses of randomized trials. J Hypertens 2014;32:2285-2295.
31. Schmieder RE, Schmidt ST, Riemer T, Dechend R, Hagedorn I, Senges J, Messerli FH, Zeymer U. Disproportional decrease in office blood pressure compared with 24-hour ambulatory blood pressure with antihypertensive treatment: dependency on pretreatment blood pressure levels. Hypertension 2014;64:1067-1072.
32. Kandzari DE, Kario K, Mahfoud F, Cohen SA, Pilcher G, Pocock S, Townsend R, Weber MA, Bohm M. The SPYRAL HTN Global Clinical Trial Program: Rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFFMED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications. Am Hear J 2016;171:82-91.
33. Bisognano JD, Bakris G, Nadim MK, Sanchez L, Kroon AA, Schafer J, Leeuw PW, de ica DA. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebocontrolled rheos pivotal trial. J Am Coll Cardiol 2011;58:765-773.
34. Bakris G, Nadim M, Haller H, Lovett E, Bisognano J. Baroreflex activation therapy safely reduces blood pressure for at least five years in a large resistant hypertension cohort. J Am Soc Hypertens 2014;8:e9.
35. Rossignol P, Massy ZA, Azizi M, Bakris G, Ritz E, Covic A, Goldsmith D, Heine GH, Jager KJ, Kanbay M, Mallamaci F, Ortiz A, Vanholder R, Wiecek A, Zoccali C, London GM, Stengel B, Fouque D. The double challenge of resistant hypertension and chronic kidney disease. Lancet 2015;386:1588-1598.
36. Bang H, Ni L, Davis CE. Assessment of blinding in clinical trials. Control Clin Trials 2004;25:143-156.
37. Pocock SJ, Bakris GL, Bhatt DL, Brar S, Fahy M, Gersh BJ. Regression to the mean in SYMPLICITY HTN-3: implications for design and reporting of future trials. J Am Coll Cardiol 2016;68:2016-2025.
38. Dahlof B, Devereux R, Faire U, De Fyhrquist F, Hedner T, Ibsen H, Julius S, Kjeldsen S, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study rationale, design, and methods. Am J Hypertens 1997;10:705-713.
39. Jung O, Gechter JL, Wunder C, Paulke A, Bartel C, Geiger H, Toennes SW. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens 2013;31:766-774.
40. Schmieder RE, Ott C, Schmid A, Friedrich S, Kistner I, Ditting T, Veelken R, Uder M, Toennes SW. Adherence to antihypertensive medication in treatment-resistant hypertension undergoing renal denervation. J Am Heart Assoc 2016;5. doi: 10.1161/JAHA.115.002343.
41. Ewen S, Meyer MR, Cremers B, Laufs U, Helfer AG, Linz D, Kindermann I, Ukena C, Burnier M, Wagenpfeil S, Maurer HH, Bohm M, Mahfoud F. Blood pressure reductions following catheter-based renal denervation are not related to improvements in adherence to antihypertensive drugs measured by urine/plasma toxicological analysis. Clin Res Cardiol 2015;104:1097-1105.
42. Patel HC, Hayward C, Ozdemir BA, Rosen SD, Krum H, Lyon AR, Francis DP, Mario di C. Magnitude of blood pressure reduction in the placebo arms of modern hypertension trials: implications for trials of renal denervation. Hypertension 2015;65:401-406.
43. Tiroch K, Sause A, Szymanski J, Nover I, Leischik R, Mann JFE, Vorpahl M, Seyfarth M. Intraprocedural reduction of the veno-arterial norepinephrine gradient correlates with blood pressure response after renal denervation. EuroIntervention 2015;11:824-834.
44. Jong MR, De Adiyaman A, Gal P, Smit JJJ, Delnoy Pphm Heeg JE, Hasselt Baam Van Lau EOY, Persu A, Staessen JA, Misier ARR, Steinberg JS, Elvan A. Renal nerve stimulation-induced blood pressure changes predict ambulatory blood pressure response after renal denervation. Hypertension 2016;68:707-714.
45. Ikeno F, Lambert D, Arjun MD. Transluminal imaging of renal nerves using optical coherence tomography. J Am Coll Cardiol 2014;64:B124.
46. Mahfoud F, Moon LB, Pipenhagen CA, Jensen JA, Pathak A, Papademetriou V, Ewen S, Linz D, Bohm M. Catheter-based radio-frequency renal nerve denervation lowers blood pressure in obese hypertensive swine model. J Hypertens 2016;34:1854-1862.
47. Tzafriri AR, Keating JH, Markham PM, Spognardi AM, Stanley JR, Wong G, Zani BG, Highsmith D, O'fallon P, Fuimaono K, Mahfoud F, Edelman ER. Arterial microanatomy determines the success of energy-based renal denervation in controlling hypertension. Sci Transl Med 2015;7:285ra65.
48. Booth LC, Nishi EE, Yao ST, Ramchandra R, Lambert GW, Schlaich MP, May CN. Reinnervation of renal afferent and efferent nerves at 5.5 and 11 months after catheter-based radiofrequency renal denervation in sheep. Hypertension 2015;65:393-400.
49. Ewen S, Ukena C, Linz D, Kindermann I, Cremers B, Laufs U, Wagenpfeil S, Schmieder RE, Bohm M, Mahfoud F. Reduced effect of percutaneous renal denervation on blood pressure in patients with isolated systolic hypertension. Hypertension 2015;65:193-199.
50. Mahfoud F, Bakris G, BhattDL, EslerM, Ewen S, FahyM, KandzariD, Kario K, ManciaG, Weber M, Bohm M. Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPLICITY HTN-3 and theGlobal SYMPLICITY Registry. Eur Heart J 2017;38:93-100.
51. Logan AG. Hypertension in aging patients. Expert Rev Cardiovasc Ther 2011;9:113-120.
52. Ott C, Lobo MD, Sobotka PA, Mahfoud F, Stanton A, Cockcroft J, Sulke N, Dolan E, Giet M, van der Hoyer J, Furniss SS, Foran JP, Witkowski A, Januszewicz A, Schoors D, Tsioufis K, Rensing BJ, Saxena M, Scott B, Ng GA, Achenbach S, Schmieder RE. Effect of arteriovenous anastomosis on blood pressure reduction in patients with isolated systolic hypertension compared with combined hypertension. J Am Heart Assoc 2016;5:e004234.